Clinical Trials Sponsored by Galena Biopharma, Inc

Total 381 results

Galena Biopharma, Inc.

Completed

Efficacy and Safety Study of NeuVax™ (Nelipepimut-S or E75) Vaccine to Prevent Breast Cancer Recurrence (PRESENT)

Breast Cancer With Low to Intermediate HER2 Expression

United States, United Kingdom, France, Israel, Germany, Canada, Russian Federation, Romania, Bulgaria, Czech Republic, Hungary, Poland, Ukraine
Galena Biopharma, Inc.

Completed

A Study of Anagrelide Controlled Release (GALE-401) in Patients With High Platelet Counts Due to Bone Marrow Disorders

Thrombocytosis | Myeloproliferative Neoplasms

United States
Galena Biopharma, Inc.

Completed

Observational Registry Study of Quality of Life When Treating BTcP With Abstral (RELIEF)

Quality of Life | Breakthrough Cancer Pain

United States
Galera Therapeutics, Inc.

Terminated

Effects of Intravenous GC4419 on the Incidence and Severity of Esophagitis Due to Chemoradiotherapy for Lung Cancer

Esophagitis

United States
Galera Therapeutics, Inc.

Completed

Study to Evaluate the Effects of Renal Impairment on the Pharmacokinetics, Safety and Tolerability of GC4419

Renal Impairment

United States
Galera Therapeutics, Inc.

Terminated

Phase I/II Study of SBRT and GC4711 for Centrally Located or Large NSCLC (GRECO-1)

NSCLC | SBRT | Non-metastatic

United States
Galera Therapeutics, Inc.

Completed

ROMAN: Phase 3 Trial Investigating the Effects of GC4419 on Radiation Induced Oral Mucositis in Head/Neck Cancer Patients

Oral Mucositis

United States, Puerto Rico, Canada
Galera Therapeutics, Inc.

Completed

Ph 2 Open Label Study of GC4419 to Reduce SOM Associated With Chemoradiotherapy for Head and Neck Cancer

Head and Neck Cancer | Oral Mucositis

Spain, Switzerland, Belgium, Poland, Germany, Czechia
Galera Therapeutics, Inc.

Terminated

A Trial of GC4419 in Patients With Critical Illness Due to COVID-19

Covid19 | SARS-CoV-2 Infection

United States
Galera Therapeutics, Inc.

Completed

A Study of the Effects of GC4419 on Radiation Induced Oral Mucositis in Patients With Head/Neck Cancer

Radiation Induced Oral Mucositis

United States, Canada, Puerto Rico
Galera Therapeutics, Inc.

Completed

A Phase 1 Dose Escalation Study of GC4419 in Combination With Chemoradiation for Squamous Cell Cancer of the Head & Neck

Squamous Cell Carcinoma of the Oral Cavity | Squamous Cell Carcinoma of the Oropharynx

United States
Galera Therapeutics, Inc.

Terminated

Phase 2b Study of GC4711 in Combination With SBRT for Nonmetastatic Pancreatic Cancer

Unresectable Pancreatic Cancer | Borderline Resectable Pancreatic Cancer | SBRT

United States, France, United Kingdom, Canada
Galera Therapeutics, Inc.

Completed

A Phase 1 Study of the Safety and Pharmacokinetics of GC4711 (Oral Capsule) Compared to GC4419 (IV Infusion) and GC4711 (IV Infusion) in Healthy Volunteers

Healthy Volunteers

Australia
Galera Therapeutics, Inc.

Completed

A Study Designed to Evaluate the Safety and Pharmacokinetics of Intravenously Administered Superoxide Dismutase Mimetic GC4711 in Healthy Volunteers

Healthy

Australia
Galera Therapeutics, Inc.

Completed

Study to Evaluate the Effects of 90 mg Intravenous Infusions of GC4419 on the Single Dose Pharmacokinetics of Dextromethorphan in Healthy Adult Subjects

Healthy

United States
BioPharmX, Inc.

Completed

Open Label Photo-Documentation Study Of BPX-01 Minocycline Gel

Acne Vulgaris

United States
BioPharmX, Inc.

Unknown

Topical Minocycline Gel for Inflammatory Lesions of Papulopustular Rosacea (PRISM)

Papulopustular Rosacea

United States
BioPharmX, Inc.

Completed

Administration of Oral Extended Release Minocycline for Assessment of Skin and Plasma Concentrations of Minocycline

Acne

United States
HC Biopharma Inc.

Recruiting

A Study of HC006 in Subjects With Advanced Solid Tumors

Advanced Solid Tumor

China
AiViva BioPharma, Inc.

Recruiting

Effect of AIV007 by Periocular Administration in Subjects With nAMD or DME

Diabetic Macular Edema | Neovascular Age-related Macular Degeneration

United States
Vitro Biopharma Inc.

Not yet recruiting

Safety & Efficacy of AlloRx SC® in PTHS Patients

Pitt Hopkins Syndrome
Ansun Biopharma, Inc.

Recruiting

Phase III DAS181 Lower Tract PIV Infection in Immunocompromised Subjects (Substudy: DAS181 for COVID-19): RCT Study

COVID-19 | Lower Respiratory Tract Infection | Immunocompromised | Parainfluenza

United States, Australia, China, Denmark, France, Hong Kong, Korea, Republic of, Taiwan
Acrotech Biopharma Inc.

Active, not recruiting

A Open-label Study to Assess the Long-term Safety of Difamilast Ointment 1% in Mild to Moderate Atopic Dermatitis

Atopic Dermatitis

United States
Aytu BioPharma, Inc.

Withdrawn

A Clinical Evaluation of Semen Quality Using the MiOXSYS™ System 2.0

Male Infertility

United States
Nitto BioPharma, Inc.

Active, not recruiting

A Study of NBF-006 in Non-Small Cell Lung, Pancreatic, or Colorectal Cancer

Colorectal Cancer | Pancreatic Cancer | Non-Small Cell Lung Cancer

United States
AiViva BioPharma, Inc.

Completed

Safety and Efficacy of AIV001 on Scar Formation and Keloid Recurrence Following Keloidectomy

Keloid

United States
Staidson Biopharma Inc.

Completed

The Safety and Tolerability of STSA-1005 Following Intravenous Infusion in Healthy Subjects

Healthy

United States
AiViva BioPharma, Inc.

Completed

A Safety and Efficacy Study to Evaluate Wound Healing

Wound Heal

United States
Acrotech Biopharma Inc.

Withdrawn

Phase 1 Study of Fusilev to Prevent or Reduce Mucositis in Patients With Non-Hodgkin's Lymphoma Receiving Folotyn

Non Hodgkin's Lymphoma
Acrotech Biopharma Inc.

Completed

Study of Pralatrexate in Patients With Relapsed or Refractory Cutaneous T-cell Lymphoma

Cutaneous T-cell Lymphoma

United States
Acrotech Biopharma Inc.

Completed

Phase 1/2 Study of VSLI Plus Rituximab in Patients With Relapsed and/or Refractory NHL

Non-Hodgkin's Lymphoma | Mantle Cell Lymphoma | Diffuse Large B-cell Lymphoma

United Kingdom, United States
Acrotech Biopharma Inc.

Completed

Pralatrexate and Bexarotene in Patients With Relapsed or Refractory Cutaneous T-cell Lymphoma

Mycosis Fungoides | Sezary Syndrome | Cutaneous T-cell Lymphoma | Primary Cutaneous Anaplastic Large Cell Lymphoma

United States, Italy
Acrotech Biopharma Inc.

Completed

Study of Pralatrexate to Treat Advanced or Metastatic Relapsed Transitional Cell Carcinoma of the Urinary Bladder

Carcinoma, Transitional Cell | Bladder Cancer | Bladder Neoplasm

Spain, France, Belgium, United States, Argentina, Croatia
Acrotech Biopharma Inc.

Completed

Liposomal Vincristine Plus Dexamethasone in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia

Acute Lymphoblastic Leukemia

United States
Alios Biopharma Inc.

Completed

First in Human Study of AL-335; Single Dose, Food Effect in Healthy Volunteers; Multiple Doses in Chronic Hepatitis C Genotype 1

Chronic Hepatitis C

France, Moldova, Republic of, Georgia
Ansun Biopharma, Inc.

Completed

Phase 2B Study on Safety and Therapeutic Efficacy of DAS181 in Adult Subjects With Naturally Acquired Influenza

Influenza

United States
Alios Biopharma Inc.

Completed

A Study of AL-034 to Evaluate the Safety, Tolerability and Pharmacokinetics of Single and Multiple Doses in Healthy Participants

Hepatitis B

New Zealand
Therapure Biopharma Inc

Unknown

Open-label Multicenter Phase 1 Study of TBI 302 as Second-Line Therapy in Patients With Hepatocellular Carcinoma

Hepatocellular Carcinoma

United States
Micelle BioPharma Inc

Unknown

A Sickle CEll Disease ComplicatioN Trial (ASCENT)

Sickle Cell Disease
Oncolys BioPharma Inc

Unknown

A Study of OBP-301 With Radiation Therapy in Patients With Esophageal Cancer

Esophageal Cancer

Japan
Alios Biopharma Inc.

Terminated

A Study to Assess the Safety, Tolerability and Pharmacokinetics of Repeated Dosing Regimens of AL-794 in Healthy Volunteers

Healthy

United Kingdom
Alios Biopharma Inc.

Terminated

Study of the Relative Oral Bioavailability of AL-3778 Tablets and Drug Interaction With Entecavir or Tenofovir Disoproxil Fumarate in Healthy Volunteers

Hepatitis B | Chronic Hepatitis B | Viral Hepatitis B

New Zealand
Ansun Biopharma, Inc.

Completed

A Phase II, Randomized, Double-blind, Placebo-controlled Study to Examine the Effects of DAS181 in Immunocompromised Subjects With Lower Respiratory Tract Parainfluenza Infection on Supplemental Oxygen (DAS181-2-05)

Parainfluenza

United States
Alios Biopharma Inc.

Completed

A Study to Assess the PK of AL-794 Formulations in Healthy Subjects

Influenza

United Kingdom
ReveraGen BioPharma, Inc.

Completed

A Phase 1 Single Ascending Dose and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of VBP15 in Healthy Adult Subjects

Healthy

United States
Nowarta Biopharma Inc

Completed

A Phase I/II Double-blind Safety and Efficacy Evaluation of Nowarta110 in Patients With Plantar Warts

Plantar Warts

United States
Fountain Biopharma Inc.

Completed

A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of FB825 in Healthy Volunteers

Healthy
CeNeRx BioPharma Inc.

Completed

Efficacy, Safety and Tolerability of CX157 in Treatment Resistant Depression (CX157-201)

Treatment Resistant Depression

United States
CeNeRx BioPharma Inc.

Completed

A Study of CX157 (TriRima) for the Treatment of Depression (CX157-200)

Major Depressive Disorder

United States
CeNeRx BioPharma Inc.

Unknown

Pharmacokinetic Study of CXB909 in Healthy Male Subjects

Healthy

3

Subscribe